FI3858375T3 - Hyytymishäiriön hoito antamalla rekombinanttia von Willebrand -tekijää - Google Patents

Hyytymishäiriön hoito antamalla rekombinanttia von Willebrand -tekijää Download PDF

Info

Publication number
FI3858375T3
FI3858375T3 FIEP20216368.9T FI20216368T FI3858375T3 FI 3858375 T3 FI3858375 T3 FI 3858375T3 FI 20216368 T FI20216368 T FI 20216368T FI 3858375 T3 FI3858375 T3 FI 3858375T3
Authority
FI
Finland
Prior art keywords
rvwf
use according
von willebrand
treatment
willebrand factor
Prior art date
Application number
FIEP20216368.9T
Other languages
English (en)
Finnish (fi)
Inventor
Friedrich Scheiflinger
Peter Turecek
Bruce Ewenstein
Wing Yen Wong
Tobias M Suiter
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Application granted granted Critical
Publication of FI3858375T3 publication Critical patent/FI3858375T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FIEP20216368.9T 2011-06-10 2012-06-11 Hyytymishäiriön hoito antamalla rekombinanttia von Willebrand -tekijää FI3858375T3 (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161495884P 2011-06-10 2011-06-10
US201161511901P 2011-07-26 2011-07-26
US201161523790P 2011-08-15 2011-08-15

Publications (1)

Publication Number Publication Date
FI3858375T3 true FI3858375T3 (fi) 2024-04-17

Family

ID=46321496

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP20216368.9T FI3858375T3 (fi) 2011-06-10 2012-06-11 Hyytymishäiriön hoito antamalla rekombinanttia von Willebrand -tekijää

Country Status (23)

Country Link
US (3) US9272021B2 (https=)
EP (3) EP3412305B1 (https=)
JP (3) JP6347468B2 (https=)
KR (3) KR20190041032A (https=)
CN (3) CN107412743B (https=)
AR (1) AR086904A1 (https=)
AU (5) AU2012267458A1 (https=)
CA (1) CA2838845C (https=)
DK (3) DK3858375T3 (https=)
ES (3) ES2682249T3 (https=)
FI (1) FI3858375T3 (https=)
HK (1) HK1257436A1 (https=)
HR (1) HRP20180962T1 (https=)
HU (1) HUE039317T2 (https=)
LT (1) LT2717905T (https=)
MX (2) MX350582B (https=)
PL (3) PL3858375T3 (https=)
PT (3) PT3412305T (https=)
RU (2) RU2680402C2 (https=)
SG (2) SG10201604684WA (https=)
SI (1) SI2717905T1 (https=)
TR (1) TR201808823T4 (https=)
WO (1) WO2012171031A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2682249T3 (es) * 2011-06-10 2018-09-19 Baxalta GmbH Tratamiento de una enfermedad de la coagulación mediante la administración de VWF recombinante
CN102776260B (zh) * 2012-07-26 2015-04-29 上海泰龙生物医药科技有限公司 一种高效表达重组人凝血八因子的方法
EP2796145B1 (en) * 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
NL2013007B1 (en) 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
FR3034669B1 (fr) * 2015-04-07 2020-02-14 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Nouvelle utilisation du facteur von willebrand
KR102415992B1 (ko) 2016-04-15 2022-07-04 다케다 야쿠힌 고교 가부시키가이샤 약물동역학 약물 투약 요법을 제공하는 방법 및 장치
US10896749B2 (en) 2017-01-27 2021-01-19 Shire Human Genetic Therapies, Inc. Drug monitoring tool
CA3069295A1 (en) 2017-07-07 2019-01-10 Baxalta Incorporated Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant vwf
US20190091298A1 (en) * 2017-07-07 2019-03-28 Baxalta Incorporated Treatment of patients with severe von willebrand disease undergoing elective surgery by administration of recombinant vwf
WO2019154867A1 (en) 2018-02-06 2019-08-15 Ablynx Nv Methods of treating initial episode of ttp with immunoglobulin single variable domains
CA3094644A1 (en) * 2018-03-21 2019-09-26 Baxalta Incorporated Separation of vwf and vwf propeptide by chromatographic methods
US12128090B2 (en) 2019-02-01 2024-10-29 Takeda Pharmaceutical Company Limited Methods of prophylactic treatment using recombinant VWF (rVWF)
US20220401524A1 (en) 2019-09-11 2022-12-22 Takeda Pharmaceutical Company Limited Methods of treatment related to complexes of von willebrand factor and complement c1q
KR20220150303A (ko) 2020-02-04 2022-11-10 다케다 야쿠힌 고교 가부시키가이샤 재조합 vwf의 투여에 의한 중증 폰 빌레브란트병 환자의 월경과다 치료
US20240002861A1 (en) * 2020-11-24 2024-01-04 Band Therapeutics, Llc Compositions and methods for treatment of bleeding disorders
WO2024124136A1 (en) * 2022-12-09 2024-06-13 Vega Therapeutics, Inc. Von willebrand disease animal models

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4638028A (en) 1985-04-08 1987-01-20 Goodyear Tire & Rubber Company Rubber polymerases and methods for their production and use
JPS62502589A (ja) 1985-04-11 1987-10-08 ザ・チヤイルドレンズ・メデイカル・センタ−・コ−ポレ−シヨン フオン・ビルブラント因子
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
SE504074C2 (sv) * 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
DE4435485C1 (de) * 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
AT403764B (de) * 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
AT405403B (de) * 1997-02-27 1999-08-25 Immuno Ag Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie
AT406373B (de) * 1997-02-27 2000-04-25 Immuno Ag Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie
US6531577B1 (en) 1997-12-15 2003-03-11 Hemasure Denmark A/S von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations
US6864403B1 (en) 1998-10-15 2005-03-08 E. I. Du Pont De Nemours And Company Plant protein disulfide isomerases
US20040014657A1 (en) * 2001-11-05 2004-01-22 Jan Ohrstrom Use of blood coagulation factor XIII for treating haemophilia A
WO2005012354A1 (en) * 2003-07-31 2005-02-10 Zlb Behring Gmbh Method for extending the half-life of fviii
EP1593388A1 (en) * 2004-05-05 2005-11-09 ZLB Behring GmbH Therapeutic plasma protein-concentrates containing von willebrand factor as high molecular weight multimers
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
CA2591852A1 (en) * 2004-12-27 2006-07-06 Baxter International Inc. Polymer-von willebrand factor-conjugates
EP3653699A1 (en) 2006-01-04 2020-05-20 Baxalta Incorporated Oligopeptide-free cell culture media
ES2392569T3 (es) * 2007-06-13 2012-12-11 Csl Behring Gmbh Uso de preparaciones FVIII estabilizadas VWF para administración extravascular en la terapia y el tratamiento profiláctico de trastornos de hemorragias
CA2704234A1 (en) 2007-11-09 2009-05-14 Baxter International Inc. Modified recombinant factor viii and von willebrand factor and methods of use
JP2009127455A (ja) 2007-11-20 2009-06-11 Bando Kiko Co Ltd 往復動エンジン
CN105816858B (zh) * 2007-12-28 2024-10-18 武田药品工业株式会社 重组vwf配方
ES2298096B1 (es) * 2008-01-08 2009-01-01 Grifols, S.A. Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand y utilizacionde los mismos.
KR101648734B1 (ko) * 2008-06-24 2016-08-18 체에스엘 베링 게엠베하 연장된 생체내 반감기를 갖는 인자 ｖｉｉｉ, 폰 빌레브란트 인자 또는 이들의 복합체
EP2349314B1 (en) * 2008-10-21 2013-02-27 Baxter International Inc. Lyophilized recombinant vwf formulations
AU2010279463A1 (en) * 2009-08-04 2012-03-01 Baxter Healthcare S.A. Transgenic mouse knockout for FVIII and VWF - model of hemophilia A
CA2805557A1 (en) 2010-07-08 2012-01-12 Baxter International Inc. Method of producing recombinant high molecular weight vwf in cell culture
US20120006800A1 (en) 2010-07-09 2012-01-12 Illinois Tool Works Inc. Weld bead feature communication systems and devices
ES2682249T3 (es) * 2011-06-10 2018-09-19 Baxalta GmbH Tratamiento de una enfermedad de la coagulación mediante la administración de VWF recombinante

Also Published As

Publication number Publication date
US20120316116A1 (en) 2012-12-13
US20250387455A1 (en) 2025-12-25
PT3858375T (pt) 2024-04-18
ES2682249T3 (es) 2018-09-19
US9272021B2 (en) 2016-03-01
CA2838845C (en) 2019-08-06
TR201808823T4 (tr) 2018-07-23
KR20190041032A (ko) 2019-04-19
AU2022201518A1 (en) 2022-03-24
DK2717905T3 (en) 2018-07-02
JP6347468B2 (ja) 2018-06-27
JP2019048892A (ja) 2019-03-28
AU2012267458A1 (en) 2014-01-09
JP6527114B2 (ja) 2019-06-05
AU2020200026A1 (en) 2020-01-30
US20160184403A1 (en) 2016-06-30
PL3412305T3 (pl) 2021-05-31
LT2717905T (lt) 2018-10-10
KR20140039285A (ko) 2014-04-01
CN103732244A (zh) 2014-04-16
MX2013014543A (es) 2014-06-11
EP2717905B1 (en) 2018-05-23
RU2680402C2 (ru) 2019-02-21
EP3858375B1 (en) 2024-03-20
HK1257436A1 (zh) 2019-10-18
WO2012171031A1 (en) 2012-12-13
RU2014100107A (ru) 2015-07-20
RU2628537C2 (ru) 2017-08-18
EP3412305B1 (en) 2021-01-06
AU2016202299A1 (en) 2016-05-05
PT2717905T (pt) 2018-07-02
KR20200091476A (ko) 2020-07-30
JP2017019788A (ja) 2017-01-26
EP2717905A1 (en) 2014-04-16
KR102319868B1 (ko) 2021-11-01
SI2717905T1 (sl) 2018-09-28
AU2017206235A1 (en) 2017-08-03
AU2022201518B2 (en) 2025-07-03
BR112013031795A2 (pt) 2016-12-20
PT3412305T (pt) 2021-01-29
NZ618790A (en) 2015-07-31
PL2717905T3 (pl) 2018-10-31
MX2020000083A (es) 2020-08-06
CA2838845A1 (en) 2012-12-13
ES2976169T3 (es) 2024-07-24
EP3858375A1 (en) 2021-08-04
ES2860450T3 (es) 2021-10-05
AR086904A1 (es) 2014-01-29
HUE039317T2 (hu) 2018-12-28
CN107412743A (zh) 2017-12-01
RU2019103386A3 (https=) 2022-01-24
CN108210889A (zh) 2018-06-29
CN107412743B (zh) 2021-07-02
JP2014516088A (ja) 2014-07-07
AU2017206235B2 (en) 2019-10-17
RU2019103386A (ru) 2020-08-07
KR101969515B1 (ko) 2019-04-16
PL3858375T3 (pl) 2024-05-20
SG10202002591QA (en) 2020-05-28
EP3412305A1 (en) 2018-12-12
DK3858375T3 (da) 2024-04-15
RU2017102679A (ru) 2018-12-19
SG10201604684WA (en) 2016-07-28
HRP20180962T1 (hr) 2018-10-19
MX350582B (es) 2017-09-11
RU2017102679A3 (https=) 2018-12-19
AU2016202299B2 (en) 2017-07-20
DK3412305T3 (da) 2021-03-01

Similar Documents

Publication Publication Date Title
FI3858375T3 (fi) Hyytymishäiriön hoito antamalla rekombinanttia von Willebrand -tekijää
Napoli et al. Endothelial progenitor cells as therapeutic agents in the microcirculation: an update
AU2018256635A1 (en) Methods for treating anemia
EP3970734A3 (en) Compartmentalized method of nucleic acid delivery and compositions and uses thereof
NZ602471A (en) Antagonists of activin-actriia and uses for increasing red blood cell levels
MX2014014840A (es) Peptido - mimeticos de la horquilla beta.
JP2009137992A5 (https=)
MA37400A1 (fr) Composés hétérocyclyle en tant qu'inhibiteurs de mek
MX2013000821A (es) Nuevas aminopirazoloquinazolinas.
WO2013120012A3 (en) Cdim binding proteins and uses thereof
JP2014516088A5 (https=)
TN2014000345A1 (en) Pharmaceutical preparation containing an antivirally active dihydroquinazoline derivative
AR088294A1 (es) Determinacion de polimorfismos de un nucleotido simple utiles para predecir la respuesta clinica al acetato de glatiramero
MX361722B (es) Formulación inyectable que comprende un compuesto de benzotiofeno y un aglutinante de partículas.
MX343205B (es) Peptidomiméticos de horquilla beta como antagonistas de cxc4.
EP2576576A4 (en) HETEROCYCLYL-PYRIDINYL BASE PHOSPHONIC ACID, PHARMACEUTICALLY ALLOWED SALT, COMPOSITION, AND METHOD OF USE THEREOF
WO2012177660A3 (en) Leukotoxin e/d as a new anti-inflammatory agent and microbicide
MX349364B (es) Variante de alfa-1 antitripsina novedosa, método de preparación de la misma, y uso de la misma.
HK1216007A1 (zh) 人体生长激素和白蛋白的融合、制剂及其用途
EP2398804A4 (en) ACID ADDITION SALT FROM UDENAFIL, METHOD OF MANUFACTURING THEREOF AND PHARMACEUTICAL COMPOSITION THEREWITH
BR112015022730A2 (pt) formulações de rfviii, método para conjugação covalente de rfviii com um polímero biocompatível e uso de rfviii no preparo de formulação de rfviii para tratamento de hemofilia a
EA201591095A1 (ru) Белок slurp-1 для применения в лечении глазных болезней
AR124709A2 (es) FACTOR DE VON WILLEBRAND RECOMBINANTE (rVWF) ÚTIL EN LA ENFERMEDAD DE VON WILLEBRAND O HEMOFILIA A
WO2016195338A3 (ko) 액정 나노 입자, 이의 제조방법 및 친유성 약물이 봉입된 액정 나노입자를 함유하는 약물 전달 시스템
PL404379A1 (pl) Maść